GlassScriptPhysician profile
Shonda Thrift
NPI 1902276801
$4,705.35
in general payments reported to CMS, 2019-2025
23 companies · $1,984 in 2025
The $1,984 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $155 · 2022: $674 · 2023: $923 · 2024: $970 · 2025: $1,984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,876.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,146.45 | 2021-2025 | Relistor |
| Forte Bio-Pharma LLC | $661.45 | 2021-2025 | Prolate, Nalocet, Tanlor |
| Collegium Pharmaceutical, INC. | $657.99 | 2023-2025 | Belbuca, Xtampza |
| Abbott Laboratories | $531.97 | 2024-2025 | Eterna, Octrode, Proclaim |
| Scilex Pharmaceuticals INC. | $431.90 | 2022-2025 | Ztlido |
| Boston Scientific Corporation | $224.25 | 2021-2025 | Intracept |
| Medtronic, INC. | $167.98 | 2023-2025 | Inceptiv, Intellis Adaptivestim, Vanta Adaptivestim |
| Curonix LLC | $157.19 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Spr Therapeutics, INC | $117.00 | 2022-2024 | Sprint Pns System |
| Grt US Holding, INC. | $83.02 | 2022 | |
| Nevro Corp. | $70.97 | 2022-2023 | Senza |
| Globus Medical, INC. | $67.05 | 2025 | Senza |
| Atland Pharmaceuticals, LLC | $65.19 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Hikma Pharmaceuticals USA | $56.17 | 2022 | |
| Lundbeck LLC | $54.14 | 2022-2023 | Vyepti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $45.78 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $38.51 | 2024-2025 | |
| Amgen INC. | $32.23 | 2022 | |
| Averitas Pharma INC. | $22.66 | 2024 | Qutenza |
| Amneal Pharmaceuticals LLC | $22.53 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.28 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $16.84 | 2023 | Iovera, Zilretta |
| Pfizer INC. | $14.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shonda Thrift listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.